Head to Head Review: NeurAxis (NRXS) & Its Rivals

NeurAxis (NASDAQ:NRXS) is one of 75 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare NeurAxis to similar companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, profitability and risk.

Profitability

This table compares NeurAxis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	N/A	N/A	N/A
NeurAxis Competitors	-323.19%	-39.98%	-22.95%

Valuation & Earnings

This table compares NeurAxis and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeurAxis	$2.46 million	-$4.78 million	-0.68
NeurAxis Competitors	$982.53 million	$86.05 million	6.38

NeurAxis’ peers have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 45.4% of shares of all “Electromedical equipment” companies are held by institutional investors. 14.3% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for NeurAxis and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
NeurAxis Competitors	229	736	1948	98	2.64

As a group, “Electromedical equipment” companies have a potential upside of 34.76%. Given NeurAxis’ peers higher probable upside, analysts plainly believe NeurAxis has less favorable growth aspects than its peers.

Summary

NeurAxis peers beat NeurAxis on 6 of the 11 factors compared.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.